The University Hospital Center Zagreb, Croatia, joins Clinerion’s global network of hospitals.
UHC Zagreb (in Croatian: KliniÄki bolniÄki centar (KBC) Zagreb) has 1,800 beds. The hospital conducted 51 clinical trials in 2016 and 61 in 2017. It has 39 Principal Investigators and an additional 120 doctors working on trials.
By joining Clinerion’s network of partner hospitals, UHC Zagreb brings its patients and clinicians access to the latest innovative medical treatments being developed by the pharmaceutical industry. Clinerion’s clients, international pharmaceutical companies and contract research organizations, use Clinerion’s technology solution to establish the availability and location of populations of eligible patient cohorts for enrollment in clinical trials. Clinerion’s technology makes it easy and reliable to assess whether patients of a partner hospital match the inclusion / exclusion criteria in a trial protocol.
With the addition of UHC Zagreb, Clinerion’s site network expands significantly again in Eastern Europe, allowing clients a wider selection of possible trial sites and an acceleration of their clinical trial programs in terms of time and cost savings arising from Clinerion’s technology solution. With UHC Zagreb, Clinerion’s network of hospital has expanded into twelve countries: eight countries with hospitals already integrated and announced and four countries with hospitals in the implementation phase.
“KBC Zagreb is delighted that this solution will greatly facilitate and accelerate the process of recruiting patients for clinical trials, and ultimately ensure greater availability of innovative therapies for our patients,” says Professor Ante ÄorušiÄ, PhD, MD CEO of UHC Zagreb.
“I am pleased to announce this new partnership with UHC Zagreb,” says Ian Rentsch, CEO of Clinerion. “Expansion of our global site network is key to our offering of comprehensively global patient data to support clinical research wherever necessary. UHC Zagreb offers cutting edge medical facilities, broad-based therapeutic area expertise and a large patient population, making it an ideal location for conducting clinical trials.”
About Clinerion
Clinerion enables early patient access to innovative treatments through real-patient data solutions for clinical trial patient recruitment, real-world evidence, and market access. Clinerion's technology solution accelerates clinical research by radically improving the efficiency and effectiveness of trial recruitment. Clinerion’s key patient data services include data-driven protocol optimization, site feasibility evaluation and patient identification. Clinerion’s solutions allow member hospitals to participate in leading-edge, industry-sponsored trials and save time in patient recruitment. They enable pharmaceutical companies to gain time and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which remain under the full control of participating hospitals. Clinerion is a global data technology service company headquartered in Switzerland. Clinerion's solutions comply with international patient privacy and data security regulations.
Clinerion website: www.clinerion.com
Clinerion’s technology solution: www.clinerion.com/index/OverviewOurSolutions/Clineriontechnologysolution
For more information, please contact:
Le Vin Chin
Head of Marketing and Communications
Clinerion Ltd
Margarethenstrasse 47, CH-4053 Basel, Switzerland
Tel.: +41 61 865 60 54
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
